Elcys Injection, Solution
NDC 51754-1008
Product Information
Elcys (cysteine hydrochloride) is a NDA-approved product labeled by Exela Pharma Sciences, Llc. This product is primarily utilized in pharmaceutical processing or compounding. It is supplied as a injection, solution for intravenous administration. This product entry covers the primary NDC 51754-1008 and 2 associated package configurations. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
- Intravenous - Administration within or into a vein or veins.
- Intravenous - Administration within or into a vein or veins.
Labeler & Regulatory Data
Marketing Timeline
Code Structure Chart
Product Details
What is NDC 51754-1008?
What are the uses of this product?
What are Active Ingredients of this product?
- CYSTEINE HYDROCHLORIDE 50 mg/mL - A thiol-containing non-essential amino acid that is oxidized to form CYSTINE.
- CYSTEINE HYDROCHLORIDE 50 mg/mL - A thiol-containing non-essential amino acid that is oxidized to form CYSTINE.
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- CYSTEINE HYDROCHLORIDE (UNII: ZT934N0X4W)
- CYSTEINE (UNII: K848JZ4886) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- WATER (UNII: 059QF0KO0R)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 1486165 - cysteine HCl 50 MG/ML Injectable Solution
- RxCUI: 1486165 - cysteine hydrochloride 50 MG/ML Injectable Solution
- RxCUI: 2671585 - ELCYS 50 MG/ML Injectable Solution
- RxCUI: 2671585 - cysteine hydrochloride 50 MG/ML Injectable Solution [Elcys]
- RxCUI: 2671585 - Elcys 50 MG/ML Injectable Solution
* Please review the full disclaimer at the bottom of this page.